HeartBeam partners with LIVMOR for RPM platform; terminates Ximedica deal

HeartBeam, Inc.

Partnered with LIVMOR to build HeartBeam-branded version of LIVMOR's FDA-cleared Halo+ RPM portal for physicians and patients.
Terminated prior development agreement with Ximedica, effective January 31, 2022, to proceed with LIVMOR partnership.
Customized HeartBeam Platform intended to support FDA submission of heart attack detection software for ED settings later in 2022.
Development fees paid in two equal installments; term of three years with automatic renewal unless terminated.
Senior executives of both companies will supervise the project; LIVMOR provides regulatory support for FDA clearance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.